Galleon Pharmaceuticals has named Lynne M. Brookes senior vice president and chief business officer.

Brookes joins Galleon from Cephalon where she held a variety of product management, marketing and business development positions and was most recently vice president of business development.

“Lynne is uniquely well-qualified to serve as our chief business officer because of her experience launching and managing very successful pharmaceutical products in markets that include many breathing-control-disorder patients. She provides a strong commercial perspective to complement our established drug-discovery and clinical-development teams," said James C. Mannion, Ph.D., Galleon’s president, chief executive officer and founder.